Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Melanoma

 

MK-3475 + PegIFN-2b and MK-3475 + Ipilimumab
A Phase I/II Clinical Trial to Study the Safety and Tolerability of MK-3475 + Pegylated Interferon Alfa-2b (PEG-IFN) and MK-3475 + Ipilimumab (IPI) in Subjects With Advanced Melanoma (MEL) and Renal Cell Carcinoma (RCC)

Investigator: John Thompson, MD;   Conditions: Renal Cell Carcinoma, Melanoma;    Status: Recruiting;   Study ID: NCT02089685

ALT-803 for Advanced Melanoma (9103A)
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients with Advanced Melanoma

Investigator: Kim Margolin, MD;   Conditions: Melanoma;    Status: Recruiting;   Study ID: NCT01946789

IL-2 "SELECT" for Advanced Melanoma
The High-Dose Aldesleukin (IL-2) "SELECT" Trial: A Prospective Tissue Collection Protocol to Investigate Predictive Models of Response to High-Dose IL-2 Treatments in Patients With Advance Melanoma

Investigator: Kim Margolin, MD;   Conditions: Malignant Melanoma;    Status: Recruiting;   Study ID: NCT01288963

pIL-12 Electroporation for Malignant Melanoma
A Multicenter Phase II Trial of Intratumoral pIL-12 Electroporation in Advanced Stage Cutaneous and in Transit Malignant Melanoma

Investigator: Shailender Bhatia, M.D.;   Conditions: Melanoma;    Status: Recruiting;   Study ID: NCT01502293

Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma (9031)
RADVAX: A Stratified Phase I/II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma

Investigator: Ramesh Rengan;   Conditions: Recurrent Melanoma, Stage IV Melanoma;    Status: Recruiting;   Study ID: NCT01970527

Tumor-Infiltrating Lymphocytes (TIL) for Metastatic Melanoma (2643)
Cellular Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes Following Lymphodepletion With Cyclophosphamide and Fludarabine For Patients With Metastatic Melanoma

Investigator: Sylvia M. Lee, MD;   Conditions: Recurrent Melanoma;    Status: Recruiting;   Study ID: NCT01807182

Phase I/II CD8+ NY-ESO-1 (FHCRC 2225)
Phase I/II Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ NY-ESO-1-Specific T Cell Clones and Anti-CTLA4 for Patients With Metastatic Melanoma

Investigator: Aude Chapuis, MD;   Conditions: Melanoma (Skin);    Status: Closed;   Study ID: NCT00871481

ID-LV305 for Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1
A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

Investigator: Seth M. Pollack, MD;   Conditions: Breast Cancer, Melanoma, Non-small Cell Lung Cancer, Ovarian Cancer, Sarcoma;    Status: Recruiting;   Study ID: NCT02122861

Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-Small Cell Lung Cancer, or Head and Neck Cancer
A Phase 1 Study of Recombinant Human IL15 (rhIL15) in Adults With Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Head and Neck Cancer

Investigator: John A. Thompson, MD;   Conditions: Melanoma, Kidney Cancer, Non-Small Cell Lung Cancer, Head and Neck Cancer;    Status: Recruiting;   Study ID: NCT01727076

MPDL3280A + Cobimetinib for Locally Advanced or Metastatic Cancer
A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Investigator: Laura Chow, MD;   Conditions: Neoplasms;    Status: Recruiting;   Study ID: NCT01988896

Expanded Access of MK-3475
Expanded Access of MK-3475 in Metastatic Melanoma Patients With Limited to No Treatment Options

Investigator: John A. Thompson, MD;   Conditions: Melanoma;    Status: Recruiting;   Study ID: NCT02083484